J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.

A programme looking to advance the understanding of how cancer develops has been backed with £50 million. Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford ...

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

“Measles is the most contagious of the vaccine-preventable diseases. If you are sick with COVID, and you go about your normal ...

Some health professionals have spoken out about President Donald Trump’s nomination of Robert F. Kennedy, Jr., for Secretary ...

Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.